Updated:
Shanghai ChemPartner Co.
Shanghai ChemPartner Co. invests life sciences capital generated by the ChemPartner CRO business for its founding family.
Shanghai ChemPartner Co.
Shanghai ChemPartner Co. was established to manage wealth originating from ChemPartner, a contract research organization founded in Shanghai that provides drug discovery and development services to pharmaceutical and biotech companies globally. The family office functions as a single-family office, focusing on capital preservation and strategic deployment. The office invests primarily in life sciences and healthcare services, with additional exposure to industrial technology sectors. It targets direct investments and co-investments within Asia, particularly in China, where it leverages the operating company's industry networks. Known positions include stakes in Chinese biotech startups and real estate holdings (per public record). The office maintains a lean team structure, typical of single-family offices in Asia, and does not disclose assets under management or number of professionals. It operates from Shanghai with no publicly known additional offices. Philanthropic activities are not separately reported. A key structural differentiator is the office's integration with the parent CRO business: it uses ChemPartner's commercial relationships and scientific expertise to source proprietary deal flow in life sciences. This operating-company-adjacent model allows the office to evaluate investments with domain insight that standalone family offices often lack.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Sector focus
Frequently asked questions
Who runs investment decisions at Shanghai ChemPartner Co.?
The principals of Shanghai ChemPartner Co. are not publicly named. The office likely includes senior members of the founding family of the ChemPartner CRO business. Investment decisions are made internally with input from the operating company's scientific leadership.
How does Shanghai ChemPartner Co. source proprietary deal flow?
The office leverages ChemPartner's network in the global pharmaceutical and biotech industries. As a CRO serving major drug developers, ChemPartner gains early visibility into therapeutic innovations and clinical-stage opportunities. This allows the family office to evaluate co-investments alongside existing partners.
Where does the underlying wealth come from?
The wealth originates from the founding family of ChemPartner, a Shanghai-based contract research organization. ChemPartner provides drug discovery and preclinical development services to pharmaceutical and biotech companies worldwide, generating the capital that the family office manages.
Does Shanghai ChemPartner Co. participate in fund commitments or only direct deals?
The office primarily focuses on direct investments and co-investments in life sciences and healthcare services. It may also allocate capital to venture funds that complement its strategic focus on Asian healthcare and industrial technology.
What investment stages does Shanghai ChemPartner Co. typically target?
The office targets growth-stage and pre-IPO investments in Chinese biotech and healthcare companies. It may also consider venture-stage opportunities where ChemPartner's CRO capabilities provide strategic advantages.
Is Shanghai ChemPartner Co. structured as a single family office or does it operate more like a venture firm?
Shanghai ChemPartner Co. is structured as a single-family office for the founding family of ChemPartner. While it invests in life sciences with a venture-like focus, its mandate is capital preservation and intergenerational wealth management, not fund management.
Which sectors does Shanghai ChemPartner Co. explicitly avoid?
The office avoids sectors outside its core life sciences, healthcare services, and industrial technology focus. It does not invest in financial services, real estate (beyond the family's direct holdings), or consumer businesses.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: